TSE:MFC

Manulife Financial (MFC.TO)

60.39
-0.28 (0.46%)
as of Jul 23, 2026, 6:04:18 pm Market Open.
1632 watching
0
Investor Insights
star iconJul 23, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Manulife Financial (MFC) has received mixed reviews from various experts, highlighting both its strengths and concerns. Many praise the company for its solid performance in Asia and wealth management, coupled with a healthy dividend yield, making it an attractive income stock. However, some analysts express caution due to overvaluation, suggesting that MFC may be overbought, trading at over 2x book value with slow earnings growth of around 8-9%. While the stock is seen as a reasonable long-term holding, there are calls for potential buying opportunities during market pullbacks. The general sentiment reflects a wait-and-see approach given the mixed indicators and the overall health of the financial sector.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Fair Value
review icon
Similar
SLF
WEAK BUY
He has a small position. He lightened it in the past. He would buy on a pullback. Asia looks promising. We have not seen a whole lot of growth out of their Asia operations so far, however. He has difficulty with their growth model otherwise. (Analysts’ price target is $29.00)
COMMENT
Their bet on Asia paid off. One of the major headwinds is interest rates. Over ten years you were just clipping the dividend. If you think interest rates are headed higher then you would be more bullish or if you agree with him that they are going lower then you would stay away. (Analysts’ price target is $28.58)
PAST TOP PICK
(A Top Pick May 03/18, Up 8%) They beat earnings. Still modeling good growth and trading at ridiculously low valuation. Still there.
COMMENT
It's trying to break through consolidation now or it could pause. It moves up and down and this pattern may continue, meaning falling back to the lower trading range of $22.
BUY
How to collect the dividend? It should be no problem, unless you're enrolled in a DRIP. Their yield is 4% and they certainly pay it. Their payout ratio at only 9%, which they can easily maintain. Earnings are up 10% in the recent quarter with the company quarter expected to be up another 8%, but there'll be glacial growth in the coming year of 5%. ROE of 14% is reasonable. 2020's earnings growth expected to be 9%. 5-9% earnings growth is okay. Look out for what happens to interest rates and bond yields.
DON'T BUY
Issue is the short report, though this has been resolved. Issue in general with insurers is they have difficult time making money in low interest rate environment. Trying to grow in Asia. Not expensive, and over 4% dividend yield. Hard to see where sustainable growth will come going forward. Good dividend yield and a bit of growth over time, but not an exciting growth story. It'll be stuck in the 20s.
BUY
The court ruled in MFC's favour and is now in the past. They just did an executive shake-up. He thinks MFC is going in the right direction, but keep an eye on it. Interest rates are pretty good now for the insurers. MFC has done a good job using automation to reduce costs.
BUY
SLF vs. MFC Owns MFC which has underformed SLF, so there's room for catch-up. MFC has a more attactive multiple. Its new CEO has boxed out legacy businesses to focus on growth in China which accounts for 25% of revenues. Trades at 8x forward earnings and 1x price-to-book. Also pays a good dividend.
HOLD
Short sellers? This has been a heart breaker through is career. One of Canada's largest companies and a bell weather for financials. He would buy it for the dividend and diversification away from the banks. It is unlikely to trade back to $30 soon. He would see $20 as key support.
TOP PICK
Just bought it yesterday. It broke their 200-day moving average. Insurance companies are performing well. 53% of their revenues are coming from Asia. Growing middle class n that area. 1.1 times PB. Discount to competitors and their 10 years average. Dividend yield of 4327% and P/E of 8x. (Analysts’ price target is $27.64)
PAST TOP PICK
(A Top Pick Aug 09/18, Down 5%) Shortly after that pick, the rogue short report came out, but MFC recently won that court case. MFC went through the ringer and has since (recently) bounced back. You'll do fine with this. They get a lot of growth out of Asia, and could spin off a division in the U.S. that could create shareholder value. A good Canadian investment with exposure abroad. He also owns SunLife, but MFC offers more growth. Lifecos are a good space to invest a little money in.
TOP PICK
The headwinds are now behind them. Offers good international exposure, upside and yield. Also a past top pick. A solid buy and hold. (Analysts’ price target is $27.64)
TOP PICK
The valuation is very compelling, at under 10x next year's earnings. It's strengthened its balance sheet. Asian operations. He expects more dividend increases. (Analysts’ price target is $27.68)
RISKY
SLF vs. MFC MFC is the trading stock vs. SLF is the holding stock (more than a year). Long-term, SLF has a smooth chart, and MFC has been jumpy--but you can make money on those big swings.
PAST TOP PICK
(A Top Pick May 25/18, Down 2%) MFC will come back. It trades at 10x earnings and pays over 4% yield. Peers trade at 20x earnings. The lawsuit is now gone, so this will now rise. Even now is a good entry point even though it rose 1.5% today alone.
Showing 406 to 420 of 2,283 entries